Table 1 Summary of characteristics of studies in the meta-analysis
Study | Number of patients | Treatment approaches | Genotyping methods | Age | Male (%) |
|---|---|---|---|---|---|
Z.H. Cao (2015) | 186 | Cisplatin-based chemotherapy | PCR-RFLP | 19.2 ± 9.4 | 57.53 |
Z.F. Liu (2015) | 115 | Cisplatin-based chemotherapy | MALDI-TOF MS | – | 56.52 |
Y.J. Sun (2015) | 175 | Chemotherapy | PCR-RFLP | 17.8 ± 9.7 | 66.28 |
W.P. Ji (2015) | 214 | Cisplatin-based chemotherapy | PCR-RFLP | 18.7 ± 11.5 | 62.15 |
Q. Zhang (2015) | 260 | Cisplatin-based chemotherapy | PCR-RFLP | 18.4 ± 8.5 | 43.84 |
L.M. Yang(2012) | 187 | Neoadjuvant chemotherapy | PCR-RFLP | 17.7 ± 9.6 | 56.68 |